Denali Therapeutics Inc. $DNLI Shares Sold by Yiheng Capital Management L.P.

Yiheng Capital Management L.P. cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 32.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 469,981 shares of the company’s stock after selling 230,117 shares during the quarter. Denali Therapeutics makes up approximately 0.4% of Yiheng Capital Management L.P.’s portfolio, making the stock its 13th largest holding. Yiheng Capital Management L.P. owned 0.32% of Denali Therapeutics worth $6,389,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of DNLI. Caitong International Asset Management Co. Ltd grew its position in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Denali Therapeutics during the first quarter valued at approximately $41,000. GF Fund Management CO. LTD. purchased a new position in shares of Denali Therapeutics during the fourth quarter valued at approximately $62,000. Point72 Hong Kong Ltd purchased a new position in shares of Denali Therapeutics during the fourth quarter valued at approximately $65,000. Finally, GAMMA Investing LLC lifted its stake in shares of Denali Therapeutics by 253.8% during the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock valued at $108,000 after buying an additional 5,705 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Ryan J. Watts sold 495,282 shares of the firm’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the transaction, the chief executive officer owned 253,071 shares of the company’s stock, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander O. Schuth sold 2,937 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 501,962 shares of company stock valued at $7,520,799. Company insiders own 12.50% of the company’s stock.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $15.27 on Friday. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.23 billion, a P/E ratio of -5.45 and a beta of 1.36. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The firm’s 50 day moving average is $14.44 and its two-hundred day moving average is $14.86.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same quarter in the previous year, the company posted ($0.59) EPS. Analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on DNLI shares. Robert W. Baird reduced their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Bank of America reduced their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. HC Wainwright reduced their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley reduced their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th. Finally, TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $33.62.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.